| # | Title | Journal | Year | Citations |
|---|
| 1 | Metabolic syndrome: pathophysiology, management, and modulation by natural compounds | Therapeutic Advances in Cardiovascular Disease | 2017 | 577 |
| 2 | 6-minute walking test: a useful tool in the management of heart failure patients | Therapeutic Advances in Cardiovascular Disease | 2019 | 156 |
| 3 | Review: Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? | Therapeutic Advances in Cardiovascular Disease | 2008 | 148 |
| 4 | ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension | Therapeutic Advances in Cardiovascular Disease | 2015 | 121 |
| 5 | Challenges in management of left ventricular thrombus | Therapeutic Advances in Cardiovascular Disease | 2017 | 110 |
| 6 | Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study | Therapeutic Advances in Cardiovascular Disease | 2007 | 97 |
| 7 | Cardiac remodelling and RAS inhibition | Therapeutic Advances in Cardiovascular Disease | 2016 | 96 |
| 8 | Mechanisms of alcoholic heart disease | Therapeutic Advances in Cardiovascular Disease | 2008 | 95 |
| 9 | Review: Stroke prevention: modifying risk factors | Therapeutic Advances in Cardiovascular Disease | 2008 | 92 |
| 10 | Review: Role of the augmentation index in hypertension | Therapeutic Advances in Cardiovascular Disease | 2008 | 89 |
| 11 | The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia | Therapeutic Advances in Cardiovascular Disease | 2016 | 87 |
| 12 | Pathophysiology, diagnosis, and management of aortic dissection | Therapeutic Advances in Cardiovascular Disease | 2008 | 83 |
| 13 | Review: Systemic and uteroplacental renin—angiotensin system in normal and pre-eclamptic pregnancies | Therapeutic Advances in Cardiovascular Disease | 2008 | 80 |
| 14 | Left ventricular noncompaction cardiomyopathy: updated review | Therapeutic Advances in Cardiovascular Disease | 2013 | 75 |
| 15 | The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease | Therapeutic Advances in Cardiovascular Disease | 2010 | 73 |
| 16 | Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury | Therapeutic Advances in Cardiovascular Disease | 2008 | 72 |
| 17 | Salvianolic acid B and Tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways | Therapeutic Advances in Cardiovascular Disease | 2011 | 70 |
| 18 | Review: The role of the L-arginine-nitric oxide pathway in preeclampsia | Therapeutic Advances in Cardiovascular Disease | 2008 | 65 |
| 19 | Burden of comorbidities among patients with atrial fibrillation | Therapeutic Advances in Cardiovascular Disease | 2013 | 61 |
| 20 | Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection | Therapeutic Advances in Cardiovascular Disease | 2009 | 59 |
| 21 | The role of chronic hyperviscosity in vascular disease | Therapeutic Advances in Cardiovascular Disease | 2015 | 58 |
| 22 | Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population | Therapeutic Advances in Cardiovascular Disease | 2010 | 56 |
| 23 | Nanomedicine applied to cardiovascular diseases: latest developments | Therapeutic Advances in Cardiovascular Disease | 2017 | 56 |
| 24 | Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events | Therapeutic Advances in Cardiovascular Disease | 2019 | 55 |
| 25 | Nitric oxide mechanisms of nebivolol | Therapeutic Advances in Cardiovascular Disease | 2009 | 54 |
| 26 | Review: Vascular remodeling: implications for small artery function and target organ damage | Therapeutic Advances in Cardiovascular Disease | 2007 | 53 |
| 27 | Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice | Therapeutic Advances in Cardiovascular Disease | 2013 | 50 |
| 28 | Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications | Therapeutic Advances in Cardiovascular Disease | 2015 | 50 |
| 29 | Review: Pulse pressure, arterial stiffness and wave reflections (augmentation index) as cardiovascular risk factors in hypertension | Therapeutic Advances in Cardiovascular Disease | 2008 | 48 |
| 30 | Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Therapeutic Advances in Cardiovascular Disease | 2019 | 47 |
| 31 | Review: Endothelial progenitor cells: markers of vascular reparative capacity | Therapeutic Advances in Cardiovascular Disease | 2008 | 46 |
| 32 | Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart | Therapeutic Advances in Cardiovascular Disease | 2010 | 46 |
| 33 | New parenteral anticoagulants in development | Therapeutic Advances in Cardiovascular Disease | 2011 | 46 |
| 34 | Exploration of pharmacological interventions to prevent isoproterenol-induced myocardial infarction in experimental models | Therapeutic Advances in Cardiovascular Disease | 2014 | 46 |
| 35 | Epidemic of cardiometabolic diseases: a Latin American point of view | Therapeutic Advances in Cardiovascular Disease | 2011 | 45 |
| 36 | Low dietary sodium intake is associated with enhanced vascular endothelial function in middle-aged and older adults with elevated systolic blood pressure | Therapeutic Advances in Cardiovascular Disease | 2009 | 44 |
| 37 | The role of endothelial cells and their progenitors in intimal hyperplasia | Therapeutic Advances in Cardiovascular Disease | 2010 | 44 |
| 38 | Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors | Therapeutic Advances in Cardiovascular Disease | 2010 | 43 |
| 39 | Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease | Therapeutic Advances in Cardiovascular Disease | 2013 | 42 |
| 40 | The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease | Therapeutic Advances in Cardiovascular Disease | 2018 | 42 |
| 41 | Review: Hypercholesterolemia-associated endothelial progenitor cell dysfunction | Therapeutic Advances in Cardiovascular Disease | 2008 | 39 |
| 42 | Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis | Therapeutic Advances in Cardiovascular Disease | 2009 | 39 |
| 43 | Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin–angiotensin system blockers | Therapeutic Advances in Cardiovascular Disease | 2012 | 39 |
| 44 | Mega clinical trials which have shaped the RAS intervention clinical practice | Therapeutic Advances in Cardiovascular Disease | 2016 | 39 |
| 45 | Understanding mechanisms of hypertension in systemic lupus erythematosus | Therapeutic Advances in Cardiovascular Disease | 2017 | 38 |
| 46 | Potential use of endothelial progenitor cells for regeneration of the vasculature | Therapeutic Advances in Cardiovascular Disease | 2009 | 37 |
| 47 | Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials | Therapeutic Advances in Cardiovascular Disease | 2010 | 37 |
| 48 | Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention | Therapeutic Advances in Cardiovascular Disease | 2011 | 37 |
| 49 | Review: The therapeutic role of RAS blockade in chronic heart failure | Therapeutic Advances in Cardiovascular Disease | 2008 | 36 |
| 50 | Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study | Therapeutic Advances in Cardiovascular Disease | 2010 | 36 |
